11th Feb 2025 A plain language summary of the EV-302/KEYNOTE-A39 study: evaluating the effectiveness and safety of enfortumab vedotin (EV) with pembrolizumab in advanced urothelial cancer
18th Jan 2024 Plain language summary: looking at the enfortumab vedotin plus pembrolizumab treatment combination for untreated locally advanced or metastatic urothelial cancer
